Bristol-Myers Squibb (NYSE:BMY) had its price objective hosited by JPMorgan Cazenove from $48.00 to $50.00 in a report released on Friday, Stock Ratings Network.com reports.
A number of other analysts have also recently weighed in on BMY. Analysts at BMO Capital Markets cut their price target on shares of Bristol-Myers Squibb from $52.00 to $48.00 in a research note to investors on Friday. They now have a market perform rating on the stock. Separately, analysts at Sanford C. Bernstein raised their price target on shares of Bristol-Myers Squibb from $45.00 to $46.00 in a research note to investors on Friday. They now have a market perform rating on the stock. Finally, analysts at Zacks reiterated a neutral rating on shares of Bristol-Myers Squibb in a research note to investors on Friday. They now have a $46.00 price target on the stock.
One analyst has rated the stock with a sell rating, eight have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $45.33.
Bristol-Myers Squibb (NYSE: BMY) opened at 43.76 on Friday. Bristol-Myers Squibb has a 52-week low of $30.64 and a 52-week high of $49.57. The stock’s 50-day moving average is currently $45.25. The company has a market cap of $71.878 billion and a price-to-earnings ratio of 53.63.
The company also recently declared a quarterly dividend, which is scheduled for Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, July 2nd.
Bristol-Myers Squibb Company (NYSE: BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.